Kura Oncology (NASDAQ:KURA) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research note released on Thursday, Benzinga reports. They currently have a $32.00 price target on the stock.

Several other equities research analysts have also recently commented on KURA. UBS Group began coverage on Kura Oncology in a report on Thursday. They set a “buy” rating and a $27.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Monday, September 9th. Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a report on Tuesday. JMP Securities reiterated a “market outperform” rating and issued a $32.00 price target on shares of Kura Oncology in a research report on Monday, August 12th. Finally, StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $28.83.

Kura Oncology Stock Up 1.1 %

KURA traded up $0.19 on Thursday, reaching $17.97. The company’s stock had a trading volume of 14,525 shares, compared to its average volume of 898,404. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -8.19 and a beta of 0.84. The business’s 50 day moving average is $19.38 and its 200 day moving average is $20.11. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94 and a quick ratio of 14.94. Kura Oncology has a 1 year low of $7.52 and a 1 year high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.04. During the same quarter in the prior year, the company posted ($0.53) EPS. The company’s quarterly revenue was up .0% compared to the same quarter last year. As a group, research analysts forecast that Kura Oncology will post -2.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Kura Oncology

Hedge funds and other institutional investors have recently modified their holdings of the stock. Avoro Capital Advisors LLC lifted its stake in Kura Oncology by 29.2% during the first quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after buying an additional 870,000 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Kura Oncology by 50.1% in the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock worth $35,653,000 after purchasing an additional 577,732 shares in the last quarter. Affinity Asset Advisors LLC boosted its holdings in shares of Kura Oncology by 281.4% during the first quarter. Affinity Asset Advisors LLC now owns 730,492 shares of the company’s stock worth $15,581,000 after purchasing an additional 538,957 shares during the period. Sofinnova Investments Inc. grew its position in Kura Oncology by 64.4% during the second quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after purchasing an additional 323,303 shares in the last quarter. Finally, Armistice Capital LLC increased its stake in Kura Oncology by 14.7% in the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after buying an additional 302,000 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.